Comparative Pharmacology
Head-to-head clinical analysis: MYOSCINT versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYOSCINT versus NEPHROSCAN.
MYOSCINT vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myoscint (indium In 111 imciromab pentetate) is a radiolabeled monoclonal antibody that binds to cardiac myosin, specifically targeting myosin heavy chains exposed in necrotic myocardial cells. It is used for imaging myocardial necrosis following acute myocardial infarction.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Adults: 1-2 mCi (37-74 MBq) intravenously as a single dose. Imaging can be repeated after 6-24 hours with same dose if needed.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life is 6–8 hours; clinically, this allows same-day imaging post-injection.
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal; approximately 70% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination (<5%).
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical